SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending, with community members highlighting its potential involvement in the "Golden Dome" defense project and recent strong earnings. Some see a breakout opportunity if it can push through range highs on volume, while others discuss the company's technology and growth potential in the aerospace and defense sector. There is also discussion around possible short attacks.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending downwards as investors react to concerns about AI revenue specifics and lower margin expectations despite strong earnings and a substantial AI product backlog, leading to a significant stock decline. The community is debating whether this drop is an overreaction or a correction, with some seeing a buying opportunity while others anticipate further declines. Some traders point towards analysts' upgrades and strong fundamentals as reasons for an imminent rebound.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards as the community discusses recent price drops and potential support levels, with some speculating about market manipulation and tax-loss harvesting. Concerns about an AI bubble and the company's debt are circulating, while others maintain a long-term bullish outlook based on IREN's Microsoft deal and growth potential in the data center space. Community members are debating the impact of Bitcoin's performance and potential news catalysts on IREN's future price movement.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to a significant surge in price and volume, sparking discussions about a potential short squeeze. The community is actively debating its overnight trading activity and potential for further gains, drawing comparisons to other high-flying stocks. Some traders are pointing to the company's focus on AI-powered robotics as a reason for optimism, while others are wary of a potential pump and dump.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim data from its RAD 101 Phase 2b imaging trial, showing promising results in brain metastases patients. The community is discussing the potential for a short squeeze and speculating on price targets, with some highlighting the company's cash runway through 2026. High trading volume and aggressive volatility, paired with a webinar scheduled, are contributing to the heightened interest.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound's price action is sparking debate, with some traders calling out potential pump-and-dump schemes while others see an opportunity amidst market volatility. Community members are weighing the impact of treasury levels, governance, and competition from other DeFi protocols like AAVE. Discussions also touch on potential real-world asset (RWA) tokenization and the Compound Foundation's activities.

Didi Global, Inc. engages in the operation of mobility platforms that provides ride hailing and other related services. It operates through the following segments: China Mobility, International, and Other Initiative. The China Mobility segment consists of ride hailing, taxi hailing, chauffeur and hitch services. The International segment includes ride hailing and food delivery services in international markets, outside of China. The Other Initiatives segment mainly consists of bike and e-bike sharing, certain auto solutions, intra-city freight, community group buying, autonomous driving, and financial services. The company was founded by Wei Cheng, Qing Liu, Bo Zhang and Rui Wu on January 11, 2013 and is headquartered Beijing, China.

DiDi Global Inc - ADR

DiDi Global (DIDIY) is trending due to speculation around its potential Hong Kong relisting, fueled by positive movement in Chinese markets and analyst upgrades. The community discusses the likelihood of the relisting, potential timelines, and the impact of share buybacks and the recent class action settlement. Some investors express frustration with the stock's volatility while remaining optimistic about its long-term potential, especially in the robotaxi market.

Numeraire

Numeraire is trending amid discussions of its low circulating supply and potential for significant price movement, with some community members eyeing previous all-time highs. Talk centers on its unique position as an AI-driven crypto hedge fund and speculation that major players are accumulating the token. Recent performance and the possibility of increased AUM are also fueling bullish sentiment.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending amid mixed sentiment, with some traders expressing frustration over its price action and comparing it unfavorably to Bitcoin and other altcoins. Community discussions revolve around whether the project is a viable long-term investment or a failing endeavor, while others point to developments and partnerships in Japan as potential catalysts. Technical analysis and predictions for potential pumps and dumps are also circulating.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

KYTX is experiencing increased attention due to analyst upgrades and positive phase 2 trial results for its CAR-T therapy in stiff person syndrome, with plans for FDA submission in 2026. Despite a recent equity offering causing a temporary dip, the community sees long-term potential, particularly in the broader application of CAR-T for autoimmune diseases. Community members are actively discussing potential price targets and the possibility of an acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5 Best-Performing Leveraged ETFs of Last Week

Cannabis, space, nat gas & auto led last week's leveraged ETF winners. MSOX, RKLX, KOLD, VOYX and CVNX posted outsized gains despite tech weakness.

Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO

Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Top-Performing ETF Areas of August That Are Up At Least 20% 

ETFs tied to Cannabis, Asia, China, materials and bitcoin miners led August's gains in Wall Street. ETFs like WEED, KSTR, CNXT, GBUG and WGMI won in August.

Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification

Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.


Tilray Brands, Inc. faces a regulatory reckoning: regain Nasdaq’s minimum bid price requirements soon or possibly get delisted from the exchange.&nbsp;The retail trading community on Stocktwits believes the cannabis and beer company will soon overcome this hurdle.Leamington, Canada-based Tilray received a non-compliance notice from Nasdaq on Tuesday after its stock failed to maintain the exchange’s $1 minimum closing bid price requirement for 30 consecutive business days.Shares of Tilray have lost more than half their value this year, as cannabis-linked stocks continue to struggle amid stalled federal legalization efforts.The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.If the company fails, it may transfer to the Nasdaq Capital Market for another 180-day extension — provided it meets other listing requirements and notifies Nasdaq of its plan to fix the issue, possibly through a reverse stock split.&nbsp;If Nasdaq still determines the company cannot regain compliance, its stock will face delisting.On Stocktwits, sentiment for Tilray ended on a slightly higher ‘bullish’ level on Wednesday amid a 45% jump in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/TLRY_sentiment_and_message_volume_as_of_Macrh_26_png_785b929906.webp" alt="TLRY sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>TLRY sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One user expressed hopes of Nasdaq being lenient with its process and said there were “zero” delisting fears because, with the extension, Tilray has until April 2026 to regain compliance.<stembedurl>https://stocktwits.com/Finance88/message/609341203</stembedurl>Another user said the company is “vertically scaled to be dominant from flower to drinks to pharma,” pointing to its products being available on the multinational supermarket chain Whole Foods, which is owned by Amazon.com.<stembedurl>https://stocktwits.com/Heb1972/message/609362664</stembedurl>Several retail investors on Stocktwits hope Tilray does not resort to a reverse stock split.<stembedurl>https://stocktwits.com/Rs1015/message/609258289</stembedurl>In January, Tilray’s stock was dealt a blow after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tlry-stock-slides-after-q2-2025-results/chGWAd2RZD">reported</a> disappointing quarterly results and projected a $20 million revenue blow for 2025 from cutting back on certain alcohol beverage brands.Meanwhile, the company said Wednesday that the Massachusetts Superior Court dismissed a lawsuit filed by a shareholder against the company and its subsidiary Hexo.The plaintiff claimed Tilray failed to inform shareholders about Hexo’s corporate actions in late 2022 and its 2023 acquisition, allegedly causing financial losses. He sought nearly $8 million in damages.&nbsp;According to Koyfin data, short interest on Tilray has shot up from 12.7% at the start of the year to 17.3% as of the last week.The stock trades at a significant 180% discount to Wall Street’s average price target of $1.83. Out of 13 analysts covering it, nine rate it ‘hold’ and four ‘buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of a Canadian pharmaceutical and cannabis company, Tilray, is seen on a smartphone and a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Tilray Retail Bulls See Nasdaq Compliance On The Horizon, Shareholder Lawsuit Victory Adds Cheer

The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.

Equity

The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.


Shares of cannabis retailer Curaleaf Holdings dropped nearly 10% on Monday after the company posted mixed fourth-quarter earnings.&nbsp;While Curaleaf reported a profit of $12.4 million, or $0.02 per share, compared with a $5 million loss from the same period last year, revenue declined to $331.1 million from $345.3 million.Chairman and CEO Boris Jordan highlighted the company's profitability metrics, noting that Curaleaf achieved an adjusted gross margin of 48% and an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $76 million.&nbsp;He also pointed to the company's strengthened cash position, with $107 million in cash at year-end, and operating and free cash flow of $163 million and $70 million, respectively."Over the past two quarters, my primary objective has been to amplify our strengths, address key challenges, and stabilize the business," Jordan said."Having successfully achieved this, we are now forging ahead with our 'Return to our ROOTS' initiative—an ambitious strategy centered on driving organic growth, optimizing margins and cash flow, and reducing debt."Message volume for Curaleaf surged 366% on Stocktwits following the earnings release, with posts reflecting a divide between bullish and bearish sentiment.&nbsp;One trader emphasized Curaleaf's dominant position in the industry, its $1.34 billion annual sales, and improving cash flow, arguing that the company remains well-positioned despite foreign exchange headwinds affecting international sales.&nbsp;<stembedurl>https://stocktwits.com/angelfromsky/message/606622013</stembedurl>Others, however, focused on the revenue decline, with one trader calling it a "solid miss as usual" and another predicting that the stock would slip below $1.<stembedurl>https://stocktwits.com/symbol/CURLF/earnings</stembedurl>Curaleaf and its industry peers have been&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/trulieve-curaleaf-and-green-thumb-launch-hemp-based-thc-drinks-as-cannabis-reforms-stall-2f03d249">expanding</a> into THC-infused beverages as federal cannabis legalization efforts stall.&nbsp;Last week, the company announced a partnership with Total Wine &amp; More to distribute its Select Zero Proof line of hemp-derived THC seltzers.Curaleaf stock has lost over 28% this year.&nbsp;According to Koyfin data, it trades about 240% below the average price target of $4.02 from 10 analysts. Seven rate it a 'buy,' one assigns a 'strong buy,' and two have a 'hold' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Curaleaf medical cannabis dispensary in Forest Hills, Queens, NY. (Photo by: Lindsey Nicholson/UCG/Universal Images Group via Getty Images)

Curaleaf's Q4 Profit Swing Ignites Retail Chatter, But Shrinking Revenue Dampens The High

Chairman and CEO Boris Jordan pointed to the company's strengthened cash position, with $107 million in cash at year-end, and operating and free cash flow of $163 million and $70 million.

Shares of Tilray Brands tumbled over 12% on Thursday, hitting their lowest point since Dec. 20, as the cannabis and beer company reported disappointing fiscal second-quarter (Q2) results and projected a $20 million revenue blow for 2025.The company posted a Q2 net loss of $85.3 million, nearly doubling its year-ago loss of $46.2 million.&nbsp;Cannabis net revenue fell slightly to $66 million from $67 million in the prior year.&nbsp;While overall Q2 revenue rose 8.8% year-over-year to $211 million, it missed Wall Street’s estimate of $216.33 million.Tilray also launched “Project 420,” a $25 million initiative to streamline its beverage business.&nbsp;The plan involves cutting back on certain alcohol beverage brands,&nbsp;which will contribute to the $20 million anticipated revenue impact for fiscal 2025.&nbsp;The company cited prioritizing key products and discontinuing underperforming stock keeping units (SKUs) as reasons for the dip.&nbsp;For the six months ended Nov. 30, 2024, the company reported a $6.0 million reduction in net sales, driven by the prioritization of certain products in key markets.&nbsp;An additional $2.0 million decline resulted from the decision to discontinue specific SKUs due to market conditions, Tilray said.However,&nbsp;the firm expects the move to be offset by innovation in new beverage categories and brand extensions over the next 18 months.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TLRY_sentiment_and_message_volume_Jan_10_premarket_d6cc8d488d.png" alt="TLRY sentiment and message volume Jan 10 premarket.png" width="1318" height="324"><figcaption>TLRY sentiment and message volume Jan 10 as of 11 am ET | source: Stocktwits</figcaption></figure>Despite the underwhelming financial performance, retail investors on Stocktwits remained surprisingly bullish.&nbsp;Many speculated on the possibility of a reverse stock split and expressed optimism about management’s potential for a turnaround.&nbsp;<stembedurl>https://stocktwits.com/PerCentInvestments/message/599550073</stembedurl><stembedurl>https://stocktwits.com/PerCentInvestments/message/599550073</stembedurl><stembedurl>https://stocktwits.com/Finer1m2/message/599547388</stembedurl><stembedurl>https://stocktwits.com/Big_Fish_76/message/599462909</stembedurl>There was also some solace in Tilray breaking even on an adjusted basis, outperforming analysts’ expectations of a $0.03 per share loss.<a href="https://stocktwits.com/symbol/TLRY">Tilray's stock</a> lost 34% in 2024.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tilray Stock Dips To 4-Week Low On $20M Revenue Blow Projection For 2025, But Retail’s Still Riding High

Tilray launched “Project 420,” a $25 million initiative to streamline its beverage business that involves cutting back on certain alcohol brands.

Current Price	$32.50
Prev Close	$34.82
Open	$38.08
Dividend Yield	N/A
50-Day Moving Average	$26.06
Beta	N/A
Avg. Volume	13,001.00
PE Ratio	N/A

52-Week High	$38.08
52-Week Low	$13.96
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

CNBS
Amplify Seymour Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Latest CNBS News

CNBSAmplify Seymour Cannabis ETF